CN109311990A - 使用CD32B x CD79B结合分子治疗炎症性疾病和病症的方法 - Google Patents

使用CD32B x CD79B结合分子治疗炎症性疾病和病症的方法 Download PDF

Info

Publication number
CN109311990A
CN109311990A CN201780034851.XA CN201780034851A CN109311990A CN 109311990 A CN109311990 A CN 109311990A CN 201780034851 A CN201780034851 A CN 201780034851A CN 109311990 A CN109311990 A CN 109311990A
Authority
CN
China
Prior art keywords
ser
cd32b
val
cd79b
lys
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201780034851.XA
Other languages
English (en)
Chinese (zh)
Inventor
陈蔚
保罗·A·摩尔
N·B·潘迪亚
埃兹奥·泊韦尼
J·M·威金顿
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Macrogenics Inc
Original Assignee
Macrogenics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Macrogenics Inc filed Critical Macrogenics Inc
Publication of CN109311990A publication Critical patent/CN109311990A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/283—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/626—Diabody or triabody
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Dermatology (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201780034851.XA 2016-06-07 2017-06-06 使用CD32B x CD79B结合分子治疗炎症性疾病和病症的方法 Pending CN109311990A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662346717P 2016-06-07 2016-06-07
US62/346,717 2016-06-07
US201662432328P 2016-12-09 2016-12-09
US62/432,328 2016-12-09
PCT/US2017/036079 WO2017214096A1 (en) 2016-06-07 2017-06-06 Methods for the use of cd32b x cd79b-binding molecules in the treatment of inflammatory diseases and disorders

Publications (1)

Publication Number Publication Date
CN109311990A true CN109311990A (zh) 2019-02-05

Family

ID=60578080

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201780034851.XA Pending CN109311990A (zh) 2016-06-07 2017-06-06 使用CD32B x CD79B结合分子治疗炎症性疾病和病症的方法

Country Status (11)

Country Link
US (1) US20190322741A1 (https=)
EP (1) EP3464378A4 (https=)
JP (3) JP2019521103A (https=)
KR (3) KR20220143769A (https=)
CN (1) CN109311990A (https=)
AU (1) AU2017278329B2 (https=)
BR (1) BR112018075303A2 (https=)
MX (2) MX2018015265A (https=)
RU (1) RU2022101891A (https=)
TW (1) TW201742633A (https=)
WO (1) WO2017214096A1 (https=)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114502587A (zh) * 2019-07-30 2022-05-13 普瑞文森生物有限公司 通过非耗竭性b细胞抑制剂降低免疫原性的方法和组合物
WO2023011338A1 (zh) * 2021-08-02 2023-02-09 信达生物制药(苏州)有限公司 抗CD79b×CD3双特异性抗体及其用途

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA201790719A1 (ru) * 2014-09-26 2017-07-31 Макродженикс, Инк. Биспецифические моновалентные диатела, которые способны связывать cd19 и cd3, а также их применения
EP3532497B1 (en) * 2016-10-26 2024-07-24 The Board of Trustees of the Leland Stanford Junior University Modified immunoglobulin hinge regions to reduce hemagglutination
CN113194966A (zh) * 2018-10-03 2021-07-30 柰裴斯生命科学公司 抗cd79抗体及其应用
JP2022544053A (ja) * 2019-07-30 2022-10-17 プロヴェンション・バイオ・インコーポレイテッド 非枯渇性ｂ細胞阻害剤によって免疫原性を低下させるための方法および組成物
US20240239912A1 (en) * 2020-04-10 2024-07-18 The Board Of Trustees Of The Leland Stanford Junior University Targeted reduction of activated immune cells
JP2023548848A (ja) * 2020-11-01 2023-11-21 プロヴェンション・バイオ・インコーポレイテッド ループスを処置するための方法および組成物

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015021089A1 (en) * 2013-08-09 2015-02-12 Macrogenics, Inc. Bi-specific monovalent fc diabodies that are capable of binding cd32b and cd79b and uses thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9963510B2 (en) * 2005-04-15 2018-05-08 Macrogenics, Inc. Covalent diabodies and uses thereof
US9284375B2 (en) * 2005-04-15 2016-03-15 Macrogenics, Inc. Covalent diabodies and uses thereof
US11384149B2 (en) * 2013-08-09 2022-07-12 Macrogenics, Inc. Bi-specific monovalent Fc diabodies that are capable of binding CD32B and CD79b and uses thereof
AU2016207758C1 (en) * 2015-01-13 2020-05-28 New Zealand Institute For Bioeconomy Science Limited Agricultural composition

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015021089A1 (en) * 2013-08-09 2015-02-12 Macrogenics, Inc. Bi-specific monovalent fc diabodies that are capable of binding cd32b and cd79b and uses thereof

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
MARIA-CONCETTA VERI等: "《Therapeutic control of B cell activation via recruitment of Fcgamma receptor IIb (CD32B) inhibitory function with a novel bispecific antibody scaffold》", 《ARTHRITIS & RHEUMATISM》 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114502587A (zh) * 2019-07-30 2022-05-13 普瑞文森生物有限公司 通过非耗竭性b细胞抑制剂降低免疫原性的方法和组合物
WO2023011338A1 (zh) * 2021-08-02 2023-02-09 信达生物制药(苏州)有限公司 抗CD79b×CD3双特异性抗体及其用途

Also Published As

Publication number Publication date
JP2019521103A (ja) 2019-07-25
KR20220143769A (ko) 2022-10-25
WO2017214096A1 (en) 2017-12-14
MX2024005841A (es) 2024-05-27
RU2022101891A (ru) 2022-02-07
JP2024102146A (ja) 2024-07-30
RU2018145971A3 (https=) 2020-09-03
KR20190016079A (ko) 2019-02-15
EP3464378A4 (en) 2020-06-17
AU2017278329B2 (en) 2024-08-08
TW201742633A (zh) 2017-12-16
KR20250021614A (ko) 2025-02-13
AU2017278329A1 (en) 2019-01-03
RU2018145971A (ru) 2020-07-10
JP2022120061A (ja) 2022-08-17
US20190322741A1 (en) 2019-10-24
BR112018075303A2 (pt) 2019-04-30
MX2018015265A (es) 2019-09-06
EP3464378A1 (en) 2019-04-10

Similar Documents

Publication Publication Date Title
JP6979447B2 (ja) 二重特異性ダイアボディ分子、薬学的組成物及びそれらの使用
TWI788327B (zh) 能夠結合cd137和腫瘤抗原的雙特異性結合分子及其用途
JP6432121B2 (ja) Ｐｄｌ−１抗体、その医薬組成物及びその使用
KR102294018B1 (ko) CD32B 및 CD79b에 결합할 수 있는 이중특이성 1가 Fc 디아바디 및 그것의 용도
CN109311990A (zh) 使用CD32B x CD79B结合分子治疗炎症性疾病和病症的方法
US20190002563A1 (en) Bispecific Monovalent Diabodies That are Capable of Binding B7-H3 and CD3, and Uses Thereof
CN109310762A (zh) 联合疗法
CN109476763A (zh) 双特异性蛋白质及其制备方法
CN107484416A (zh) 能够结合cd19和cd3的双特异性单价双抗体及其用途
ES3056908T3 (en) Adam9-binding molecules, and methods of use thereof
WO2021170082A1 (zh) 抗cd47/抗pd-l1抗体及其应用
CA3128104A1 (en) Anti-pd-1 antibody, antigen-binding fragment thereof and pharmaceutical use thereof
JP7837331B2 (ja) Ｃｌｄｎ６及びｃｄ３に選択的に結合するポリペプチド構築物
US20240190989A1 (en) Anti-cea and anti-cd137 multispecific antibodies and methods of use
WO2022206976A1 (zh) 靶向cldn18.2的抗原结合蛋白及其用途
WO2022127066A9 (zh) 一种特异性中和辅助性T细胞TGF-β信号的双特异性抗体、其药物组合及其用途
RU2772434C2 (ru) Способы применения cd32b x cd79b-связывающих молекул при лечении воспалительных заболеваний и расстройств
TWI894360B (zh) 抗tigit抗體及雙抗體和它們的應用
RU2805648C2 (ru) Биспецифические связывающие молекулы, способные связывать cd137 и опухолевые антигены, и варианты их применения
HK40051187B (zh) 能结合cd32b和cd79b的双特异性单价fc双抗体及其用途
CN116685606A (zh) 选择性地与cldn6和cd3结合的多肽构建体

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination